Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

Table 1

Baseline characteristics of two groups.

Group	NeuroAid	Placebo	𝑃 value
	(𝑁=100)	(𝑁=50)
Sex (male) 𝑁(%)	48 (48%)	24 (52%)	.99
Age (mean ± SD)	64.41±5.89	66.14±5.36	.08
Risk factors
Hypertension	56	31	.48
Diabetic mellitus	43	22	.90
Hyperlipidemia	48	22	.64
Ischemic heart disease	7	3	.99
Smoking	11	5	.99
Stroke details
Days since stroke	9.45±5.39	8.92±3.51	.53
Site of the hemiparesis
Right	47	24	.90
Left	53	26